**PATENT** 

## IN THE CONTENT ATES PATENT AND TRADEMARK OFFICE

Applicant: J.C. Hunt, et al.

Serial No.: Continuation of prior application No. 08/856,155, Examiner B. Brumback, Group /Art Unit 1642

File No. of prior application: 4573.US.C5

Filed: May 14, 1997

For: MOUSE MONOCLONAL ANTIBODY (5-21-3) TO HUMAN IMMUNODEFICIENCY VIRUS GP41 PROTEIN

Case No.: 4573.US.C6

CERTIFICATE OF MAILING (37 CFR 1.8 (a))

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Assistant Commissioner for Patents Box Filing Date Washington, D.C. 20231, on:

January 10, 2002

Name of person signing this certificate: Kimberly A. Iorio

Signature:

STATEMENT OF MAILING OF PATENT APPLICATION UNDER 37 C.F.R. 1.6(e)

Assistant Commissioner for Patents Box Filing Date Washington, D.C. 20231

Dear Sir:

I, Kimberly A. Iorio, an employee of Abbott Laboratories in the Patent and Trademark Department, attempted to mail the following documents, enclosed herein as Attachment A, via U.S. Express Mail addressed to the U.S. Patent and Trademark Office on November 19, 2001:

Utility Patent Application a continuation of prior application No. 08/856,155;

Fee Transmittal;

Copy of original Specification, Claims, and Abstract;

Copy of Drawings;

Copy of original Declaration and Power of Attorney;

Copy of Original Assignment;

Request for Three-Month Extension of Time, in duplicate;

Transmittal Letter; and

Two Return Receipt Postcards.

I was refused express mail service from the United States Postal Service due to government security measures, as more fully set forth in the November 16, 2001, U.S. Postal Service Memo entitled Temporary Suspension of Express Mail Service to Washington, DC ZIP Codes 202 through 205, enclosed herein as Attachment B.

Once advised that Express Mail to Washington, DC ZIP Codes 202 through 205 was suspended, I deposited the above-referenced documents along with the Suspension of Express Mail Memo with the U.S. Postal Service as First Class Mail addressed to the to

eceiph date granter

Serial No.: (not yet assigned) Attorney Docket No.: 4573.US.C5 Statement of Mailing Under 37 C.F.R. 1.6(e)

the U.S. Patent and Trademark Office, Box Patent Application, Assistant Commissioner for Patents, Washington, DC 20231-0001, enclosed herein as Attachment C.

To date, our office has not yet received verification from the U.S. Patent and Trademark Office of receipt of our above-named application. If you require additional evidence or information to determine that the above-referenced patent application was timely filed, please contact me at (847) 937-6369.

I hereby declare that all statements made on information and belief are believed to be true, and further that these statements were made with knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and such willful false statements may jeopardize the validity of the instant patent specification or any patent issuing therein.

Respectfully submitted,

Abbott Laboratories D-377, AP6D-2 100 Abbott Park Road Abbott Park, IL 60064-3500 (847) 937-6369 (847) 938-2623 FAX



### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: J.C. Hunt, et al.

Serial No.: Continuation of prior application No. 08/856,155, Examiner B. Brumback, Group /Art

Unit 1642

File No. of prior application: 4573.US.C5

Filed: May 14, 1997

For: MOUSE MONOCLONAL ANTIBODY (5 - 21-3) TO HUMAN IMMUNODEFICIENCY VIRUS GP41 PROTEIN

Case No.: 4573.US.C6

CERTIFICATE OF MAILING (37 CFR 1.8 (a))

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Assistant Commissioner for Patents Box Filing Date Washington, D.C. 20231, on:

January 10, 2002

Name of person signing this certificate: Kimberly A. Iorio

Signatur

## TRANSMITTAL LETTER

Assistant Commissioner for Patents Box Filing Date Washington D.C. 20231

Dear Sir:

Enclosed herewith is the Statement of Mailing of Patent Application Under 37 C.F.R. 1.6(e) Transmittal Letter for MOUSE MONOCLONAL ANTIBODY (5-21-3) TO HUMAN IMMUNODEFICIENCY VIRUS GP41 PROTEIN.

Also enclosed is:

Return Receipt Postcard

The Commissioner is hereby authorized to charge any additional filing fees required under 37 CFR 1.17 concerning this transaction, or to credit any overpayment, to Deposit Account No. 01-0025. A duplicate copy of this sheet is enclosed.

23492

ABBOTT LABORATORIES

Telephone: (847) 938-3137 Facsimile: (847) 938-2623

Respectfully submitted, J. C. Hunt, et al.

Dianne Casuto

Registration No. 40,943 Attorney for Applicants





#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: J.C. Hunt, et al.

Serial No.: Continuation of prior application No. 08/856,155, Examiner B. Brumback, Group /Art

Unit 1642

File No. of prior application: 4573.US.C5

Filed:

For: MOUSE MONOCLONAL ANTIBODY (5 -21-3) TO HUMAN IMMUNODEFICIENCY **VIRUS GP41 PROTEIN** 

Case No.: 4573.US.C6

Date: November 19, 2001

EXPRESS MAIL NO.: EL507386035US

Certificate of Mailing under 37 CFR §1.10:

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service as Express Mail Post Office to Addressee Service with sufficient postage in an envelope addressed to:

Assistant Commissioner for Patents Washington, D.C. 20231

on November 19, 2001

Name of person signing

this certificate: Kimberly A. Iorio

### TRANSMITTAL LETTER

**Assistant Commissioner for Patents** Washington D.C. 20231

Dear Sir:

Enclosed herewith is the Utility Patent Application Transmittal Letter of Jeffrey C. Hunt, et al., for MOUSE MONOCLONAL ANTIBODY (5-21-3) TO HUMAN IMMUNODEFICIENCY VIRUS GP41 PROTEIN.

Also enclosed are:

Fee Transmittal, in duplicate (1 Page)

Copy of Original Specification, Claims and Abstract (41 Pages)

Copy of Drawings/Figures (6 Pages)

Copy of Original Executed Declaration and Power of Attorney (2

Pages)

Copy of Original Assignment (1 Page)

Request for Three-Month Extension of Time, in duplicate

Two Return Receipt Postcards

The Commissioner is hereby authorized to charge any additional filing fees required under 37 CFR 1.17 concerning this transaction, or to credit any overpayment, to Deposit Account No. 01-0025.

A duplicate copy of this sheet is enclosed.

Abbott Laboratories Dept. 377/AP6D-2 100 Abbott Park Road Abbott Park, IL 60064-6050 Tel. No. (847) 938-3137 Fax No. (847) 938-2623

Respectfully submitted,

J.C. Hunt, et al.

Cheryl L. Becker Registration No. 35,441 Attorney for Applicant(s)



PTO/SB/17 (12/99)

Approved for use through 09/30/2000. OMB 0651-0032

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# FEE TRANSMITTAL for FY 2000

Patent fees are subject to annual revision.

Small Entity payments <u>must</u> be supported by a small entity statement, otherwise large entity fees must be paid. See Forms PTO/SB/09-12.

See 37 C.F.R. §§ 1.27 and 1.28.

TOTAL AMOUNT OF PAYMENT (\$) 1,846.00

Complete if Known						
Application Number						
Filing Date						
First Named Inventor	Jeffrey C. Hunt					
Examiner Name	B. Brumback					
Group / Art Unit	1642					
Attorney Docket No.	4573.US.C6					

METHOD OF PAYMENT (check one)					F	EE CALCULATION (continued)	
1. X The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to:					AL FE	y	
Deposit Account 01_0025	C	e pode (	·ee (\$)	Cod	e (\$)	Fee Description Fee Paid	
Account Number 01-0025	10	13	30	205	65	Surcharge - late filing fee or oath	
Deposit Abbott Laboratories		27 8	50	227	25	Surcharge - late provisional filing fee or cover sheet.	
Name Abbott Laboratories		39 13	30	139	130	Non-English specification	
Charge Any Additional Fee Required Under 37 CFR §§ 1.16 and 1.17		7 2,5	20	147	2,520	For filing a request for reexamination	
2. Payment Enclosed:	11	2 92	20*	112	920*	Requesting publication of SIR prior to Examiner action	
Check Money Other	11	1,8	40*	113	1,840*	Examiner action	
FEE CALCULATION	11	5 1	10	215	55	Extension for reply within first month	
1. BASIC FILING FEE	11	-		216		Extension for reply within second month	
Large Entity Small Entity	11			217		Extension for reply within third month 920.00	
Fee Fee Fee Fee Description Code (\$) Code (\$) Fee Paid	1	8 1,3		218		Extension for reply within fourth month	
101 690 201 345 Utility filing fee 740,00	12	8 1,8		228		Extension for reply within fifth month	
106 310 206 155 Design filing fee	11			219	•	Notice of Appeal Filing a brief in support of an appeal	
107 480 207 240 Plant filing fee	12				150	Request for oral hearing	
108 690 208 345 Reissue filing fee	12			221		Petition to institute a public use proceeding	
114 150 214 75 Provisional filling fee	1	8 1,5			1,510 55	Petition to revive - unavoidable	
SUBTOTAL (1) (5) 740.00	14	10 13 11 1,2	10			Petition to revive - unintentional	
2. EXTRA CLAIM FEES	4	ii 1,2 12 1,2				Utility issue fee (or reissue)	
Fee from	1 44			243		Design issue fee 0.00	
Extra Claims below Fee Paid Total Claims 21 -20** = 1 × 18 - 18	14			244	290	Plant issue fee 0.00	
Independent 5 300 = 2 × 84 -168	12	22 13	30	122	130	Petitions to the Commissioner	
Claims Multiple Dependent	12	23 5	50	123	50	Petitions related to provisional applications 0.00	
**or number previously paid, if greater, For Reissues, see below	12	26 24	<b>40</b>	126	240	Submission of Information Disclosure Stmt	
Large Entity Small Entity Fee Fee Fee Fee Fee Description Code (\$) Code (\$)	58	31 4	40	581	40	Recording each patent assignment per property (times number of properties)	
103 18 203 9 Claims in excess of 20	14	69 89	30	246	345	Filing a submission after final rejection (37 CFR § 1.129(a))	
102 78 202 39 Independent claims in excess of 3	14	19 69	90	249	345	For each additional invention to be	
104 260 204 130 Multiple dependent claim, if not paid						examined (37 CFR § 1.129(b))	
109 78 209 39 ** Reissue independent claims over original patent	Oth	erfee(	spec	cify)_			
110 18 210 9 **Reissue claims in excess of 20 and over original patent	Oth	erfee(	spec	cify)_			
SUBTOTAL (2) (\$) 186.00	·Re	Reduced by Basic Filing Fee Paid SUBTOTAL (3) (\$) 920.00					
SUBMITTED BY Complete (if applicable)						Complete (if applicable)	
Name (Print/Type) Cheryl L. Becker				ation y/Age		35,441 Telephone 847-938-3137	
00 1100		B		)	····	Date 11-19-01	

WARNING:

Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box -> +	Please type	a plus	sign (+)	inside	this box	<b>→</b>	+	
--	-------------	--------	----------	--------	----------	----------	---	--

PTO/SB/05 (4/98)
Approved for use through 09/30/2000. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# UTILITY PATENT APPLICATION TRANSMITTAL

Attorney Docket No. 4573.US.C6

First Inventor or Application Identifier Jeffrey C. Hunt

Title Mouse Monoclonal Antibody (5-21-3) to Human Immunodeficiency Virus GP41 Protein

Express Mail Label No. EL 5073.86035US

Express Mail Label No. EL507386035US (Only for new nonprovisional applications under 37 C.F.R. § 1.53(b)) Assistant Commissioner for Patents APPLICATION ELEMENTS ADDRESS TO: **Box Patent Application** See MPEP chapter 600 concerning utility patent application contents. Washington, DC 20231 \* Fee Transmittal Form (e.g., PTO/SB/17) 5. Microfiche Computer Program (Appendix) (Submit an original and a duplicate for fee processing) 6. Nucleotide and/or Amino Acid Sequence Submission Specification [Total Pages (if applicable, all necessary) (preferred arrangement set forth below) Computer Readable Copy - Descriptive title of the Invention - Cross References to Related Applications b. Paper Copy (identical to computer copy) - Statement Regarding Fed sponsored R & D C. Statement verifying identity of above copies - Reference to Microfiche Appendix - Background of the Invention **ACCOMPANYING APPLICATION PARTS** - Brief Summary of the Invention X Assignment Papers (cover sheet & document(s)) - Brief Description of the Drawings (if filed) 37 C.F.R.§3.73(b) Statement Power of - Detailed Description (when there is an assignee) Attorney - Claim(s) English Translation Document (if applicable) - Abstract of the Disclosure Information Disclosure Copies of IDS 0. [Total Sheets | 6 Drawing(s) (35 U.S.C. 113) Statement (IDS)/PTO-1449 Citations Preliminary Amendment Oath or Declaration Return Receipt Postcard (MPEP 503) Newly executed (original or copy) 12. (Should be specifically itemized) Copy from a prior application (37 C.F.R. § 1.63(d)) \* Small Entity Statement filed in prior application (for continuation/divisional with Box 16 completed) 3. Statement(s) Status still proper and desired **DELETION OF INVENTOR(S)** (PTO/SB/09-12) i. Certified Copy of Priority Document(s) Signed statement attached deleting (if foreign priority is claimed) inventor(s) named in the prior application, see 37 C.F.R. §§ 1.63(d)(2) and 1.33(b). Request for 3-Month 5. X \* <u>NOTE FOR ITEMS 1 & 13</u> IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY Extension of Time EES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27), EXCEPT IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28). 16. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment; of prior application No: \_08/856,155 Continuation-in-part (CIP) X Continuation Divisional Brumback, B. Group / Art Unit: 1642 Prior application information: Examiner For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 4b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts. CORRESPONDENCE ADDRESS Customer Number or Bar Code Labe I or Correspondence address below (Insert Customer No. or Attach bar code label here) Cheryl L. Becker Name Abbott Laboratories D-377, AP6D Address 100 Abbott Park Road City Abbott Park State Zip Code 60064 847-938-2623 847-938-3137 Country Telephone Name (Print/Type) Registration No. (Attorney/Agent) 35,441 Cheryl L. Becker Signature

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.